ATE142110T1 - Impfstoff adjuvans - Google Patents

Impfstoff adjuvans

Info

Publication number
ATE142110T1
ATE142110T1 AT93911614T AT93911614T ATE142110T1 AT E142110 T1 ATE142110 T1 AT E142110T1 AT 93911614 T AT93911614 T AT 93911614T AT 93911614 T AT93911614 T AT 93911614T AT E142110 T1 ATE142110 T1 AT E142110T1
Authority
AT
Austria
Prior art keywords
vaccine adjuvant
immunogen
immune response
amount effective
quinolin
Prior art date
Application number
AT93911614T
Other languages
German (de)
English (en)
Inventor
Richard L Miller
Mark A Tomai
David I Bernstein
Christopher J Harrison
Original Assignee
Minnesota Mining & Mfg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining & Mfg filed Critical Minnesota Mining & Mfg
Application granted granted Critical
Publication of ATE142110T1 publication Critical patent/ATE142110T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT93911614T 1992-04-16 1993-04-08 Impfstoff adjuvans ATE142110T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86938692A 1992-04-16 1992-04-16

Publications (1)

Publication Number Publication Date
ATE142110T1 true ATE142110T1 (de) 1996-09-15

Family

ID=25353454

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93911614T ATE142110T1 (de) 1992-04-16 1993-04-08 Impfstoff adjuvans

Country Status (17)

Country Link
US (1) US6083505A (cg-RX-API-DMAC7.html)
EP (1) EP0636031B1 (cg-RX-API-DMAC7.html)
JP (2) JP3732506B2 (cg-RX-API-DMAC7.html)
KR (1) KR100263804B1 (cg-RX-API-DMAC7.html)
AT (1) ATE142110T1 (cg-RX-API-DMAC7.html)
AU (1) AU674313B2 (cg-RX-API-DMAC7.html)
CA (1) CA2118239C (cg-RX-API-DMAC7.html)
DE (1) DE69304521T2 (cg-RX-API-DMAC7.html)
DK (1) DK0636031T3 (cg-RX-API-DMAC7.html)
ES (1) ES2092306T3 (cg-RX-API-DMAC7.html)
HU (2) HU217209B (cg-RX-API-DMAC7.html)
IL (1) IL105325A (cg-RX-API-DMAC7.html)
MX (1) MX9302199A (cg-RX-API-DMAC7.html)
NO (1) NO313864B1 (cg-RX-API-DMAC7.html)
NZ (2) NZ252020A (cg-RX-API-DMAC7.html)
WO (1) WO1993020847A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA932627B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006015585A1 (de) * 2006-04-04 2007-10-18 Mahle International Gmbh Kolben für einen Verbrennungsmotor

Families Citing this family (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
WO1998017279A1 (en) 1996-10-25 1998-04-30 Minnesota Mining And Manufacturing Company Immune response modifier compounds for treatment of th2 mediated and related diseases
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
PT1075276E (pt) * 1998-05-07 2008-01-22 Corixa Corp Composição adjuvante e métodos para sua utilização
US6518280B2 (en) 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
JP3436512B2 (ja) * 1999-12-28 2003-08-11 株式会社デンソー アクセル装置
US6894060B2 (en) * 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) * 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
GB0023008D0 (en) * 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
UA75622C2 (en) * 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6664265B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
CA2430206A1 (en) * 2000-12-08 2002-06-13 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
CA2598144A1 (en) * 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
WO2003020889A2 (en) * 2001-08-30 2003-03-13 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
WO2003094836A2 (en) * 2001-10-12 2003-11-20 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
US20040014779A1 (en) * 2001-11-16 2004-01-22 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like recptor pathways
CA2467828C (en) * 2001-11-29 2011-10-04 3M Innovative Properties Company Pharmaceutical formulations comprising an immune response modifier
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
SI1478327T1 (sl) * 2002-02-22 2015-08-31 Meda Ab Metoda za zmanjšanje in zdravljenje imunosupresije, inducirane z UV-B
US20030190308A1 (en) * 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
DE60335350D1 (de) * 2002-03-19 2011-01-27 Powderject Res Ltd Adjuvantien für dns impstoffe basierend auf imidazochinoline
US20030185835A1 (en) * 2002-03-19 2003-10-02 Braun Ralph P. Adjuvant for vaccines
AU2003216852B2 (en) * 2002-03-19 2008-09-11 Glaxo Group Limited Imidazoquinolineamines as adjuvants in HIV DNA vaccination
GB0206461D0 (en) * 2002-03-19 2002-05-01 Glaxo Group Ltd Improvements in vaccination
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
WO2003103584A2 (en) 2002-06-07 2003-12-18 3M Innovative Properties Company Ether substituted imidazopyridines
CN1671412B (zh) 2002-08-15 2010-05-26 3M创新有限公司 免疫刺激组合物及刺激免疫反应的方法
AU2003299082A1 (en) * 2002-09-26 2004-04-19 3M Innovative Properties Company 1h-imidazo dimers
AU2003287324A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Gene expression systems and recombinant cell lines
AU2003287316A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
US7091214B2 (en) 2002-12-20 2006-08-15 3M Innovative Properties Co. Aryl substituted Imidazoquinolines
WO2004060319A2 (en) 2002-12-30 2004-07-22 3M Innovative Properties Company Immunostimulatory combinations
EP1592302A4 (en) * 2003-02-13 2007-04-25 3M Innovative Properties Co METHODS AND COMPOSITIONS ASSOCIATED WITH IMMUNE RESPONSE MODIFIER COMPOUNDS AND TOLL-LIKE RECEPTOR 8
US7485432B2 (en) * 2003-02-27 2009-02-03 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
JP2006519866A (ja) 2003-03-04 2006-08-31 スリーエム イノベイティブ プロパティズ カンパニー Ｕｖ誘発性の表皮の新形成の予防的治療
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
JP2006519877A (ja) * 2003-03-07 2006-08-31 スリーエム イノベイティブ プロパティズ カンパニー １−アミノ１ｈ−イミダゾキノリン
MXPA05009694A (es) * 2003-03-13 2005-10-20 3M Innovative Properties Co Metodos para mejorar la calidad de la piel.
WO2004080292A2 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
JP2006523212A (ja) * 2003-03-13 2006-10-12 スリーエム イノベイティブ プロパティズ カンパニー 皮膚病変の診断方法
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US20040202720A1 (en) * 2003-04-10 2004-10-14 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
US6943255B2 (en) 2003-06-06 2005-09-13 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
AR044466A1 (es) * 2003-06-06 2005-09-14 3M Innovative Properties Co Proceso para la preparacion de imidazo [4,5-c] piridin-4-aminas
MXPA06001004A (es) * 2003-07-31 2006-04-27 3M Innovative Properties Co Composiciones para encapsulacion y liberacion controlada.
JP2007501251A (ja) * 2003-08-05 2007-01-25 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤化合物を使用する感染予防
CA2535120A1 (en) * 2003-08-12 2005-03-03 3M Innovative Properties Company Hydroxylamine substituted imidazo-containing compounds
US7799800B2 (en) * 2003-08-14 2010-09-21 3M Innovative Properties Company Lipid-modified immune response modifiers
WO2005020912A2 (en) * 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
US20050048072A1 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
KR101106812B1 (ko) 2003-08-27 2012-01-19 쓰리엠 이노베이티브 프로퍼티즈 컴파니 아릴옥시 및 아릴알킬렌옥시 치환된 이미다조퀴놀린
US20060216333A1 (en) * 2003-09-02 2006-09-28 Miller Richard L Methods related to the treatment of mucosal associated conditions
AU2004270201A1 (en) * 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
US20050059072A1 (en) * 2003-09-17 2005-03-17 3M Innovative Properties Company Selective modulation of TLR gene expression
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
WO2005032484A2 (en) 2003-10-03 2005-04-14 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
CA2540598C (en) 2003-10-03 2013-09-24 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
US20050096259A1 (en) * 2003-10-31 2005-05-05 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
EP1682544A4 (en) 2003-11-14 2009-05-06 3M Innovative Properties Co HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS
CN1906193A (zh) * 2003-11-14 2007-01-31 3M创新有限公司 肟取代的咪唑环化合物
SG148201A1 (en) 2003-11-25 2008-12-31 3M Innovative Properties Co Substituted imidazo ring systems and methods
WO2005051324A2 (en) * 2003-11-25 2005-06-09 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
EP1689361A4 (en) * 2003-12-02 2009-06-17 3M Innovative Properties Co THERAPEUTIC COMBINATIONS AND PROCESSES WITH IRM COMPOUNDS
CA2549216A1 (en) * 2003-12-04 2005-08-25 3M Innovative Properties Company Sulfone substituted imidazo ring ethers
US8802853B2 (en) 2003-12-29 2014-08-12 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
JP2007530450A (ja) * 2003-12-29 2007-11-01 スリーエム イノベイティブ プロパティズ カンパニー ピペラジン、［１，４］ジアゼパン、［１，４］ジアゾカン、および［１，５］ジアゾカン縮合イミダゾ環化合物
US20050239735A1 (en) * 2003-12-30 2005-10-27 3M Innovative Properties Company Enhancement of immune responses
WO2005066169A2 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
JP4991520B2 (ja) * 2004-03-15 2012-08-01 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤製剤および方法
CA2559863A1 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
EP1735010A4 (en) * 2004-04-09 2008-08-27 3M Innovative Properties Co METHODS, COMPOSITIONS AND PREPARATIONS FOR ADMINISTRATION OF IMMUNE RESPONSE MODIFIERS (MRI)
EP1755665A4 (en) * 2004-04-28 2010-03-03 3M Innovative Properties Co COMPOSITIONS AND METHODS FOR MUCOSAL VACCINATION
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
WO2005123079A2 (en) * 2004-06-14 2005-12-29 3M Innovative Properties Company Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7884207B2 (en) * 2004-06-18 2011-02-08 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
EP1786450A4 (en) * 2004-08-27 2009-11-11 3M Innovative Properties Co HIV IMMUNOSTIMATORY COMPOSITIONS
ES2384390T3 (es) * 2004-09-02 2012-07-04 3M Innovative Properties Company Sistemas cíclicos 1-alcoxi-1H-imidazo y métodos asociados
CA2578975A1 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1h imidazo ring systems and methods
US20080193468A1 (en) * 2004-09-08 2008-08-14 Children's Medical Center Corporation Method for Stimulating the Immune Response of Newborns
WO2006042254A2 (en) * 2004-10-08 2006-04-20 3M Innovative Properties Company Adjuvant for dna vaccines
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
EP1830876B1 (en) * 2004-12-30 2015-04-08 Meda AB Use of imiquimod for the treatment of cutaneous metastases derived from a breast cancer tumor
US7943609B2 (en) 2004-12-30 2011-05-17 3M Innovative Proprerties Company Chiral fused [1,2]imidazo[4,5-C] ring compounds
JP2008526757A (ja) * 2004-12-30 2008-07-24 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤製剤および方法
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
US20080188513A1 (en) * 2004-12-30 2008-08-07 Taked Pharmaceutical Company Limited 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Ethanesulfonate and 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Methanesulfonate
JP5313502B2 (ja) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー 置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
CA2597092A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
AU2006212765B2 (en) 2005-02-09 2012-02-02 3M Innovative Properties Company Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
EP1877056A2 (en) 2005-02-09 2008-01-16 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazoloý4,5-c¨ring compounds and methods
AU2006216997A1 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
WO2006086634A2 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
PL2351772T3 (pl) 2005-02-18 2017-01-31 Glaxosmithkline Biologicals Sa Białka i kwasy nukleinowe z bakterii Escherichia coli związanej z zapaleniem opon mózgowo-rdzeniowych/posocznicą
NZ560929A (en) 2005-02-18 2009-12-24 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
AU2006216798A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
WO2006091647A2 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
US8178677B2 (en) 2005-02-23 2012-05-15 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinolines
US8343993B2 (en) 2005-02-23 2013-01-01 3M Innovative Properties Company Hydroxyalkyl substituted imidazonaphthyridines
JP2008533148A (ja) 2005-03-14 2008-08-21 スリーエム イノベイティブ プロパティズ カンパニー 光線性角化症の治療方法
WO2006107853A2 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
US20080193474A1 (en) * 2005-04-25 2008-08-14 Griesgraber George W Immunostimulatory Compositions
US20100017895A1 (en) 2005-07-18 2010-01-21 Amy Weiner Small animal model for hcv replication
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
EA200800782A1 (ru) 2005-09-09 2008-08-29 Коли Фармасьютикал Груп, Инк. ПРОИЗВОДНЫЕ АМИДА И КАРБАМАТА N-{2-[4-АМИНО-2-(ЭТОКСИМЕТИЛ)-1Н-ИМИДАЗОЛО[4,5-c]ХИНОЛИН-1-IL]-1,1-ДИМЕТИЛЭТИЛ}МЕТАНСУЛЬФОНАМИДА И СПОСОБЫ
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
EP1948173B1 (en) 2005-11-04 2013-07-17 3M Innovative Properties Company Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
EP1945252B1 (en) 2005-11-04 2013-05-29 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene
EP1951302A2 (en) 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
ATE539765T1 (de) 2005-11-04 2012-01-15 Novartis Vaccines & Diagnostic Grippeimpfstoffe mit kombinationen aus teilchenförmigen adjuvantien und immunverstärkern
NZ567979A (en) * 2005-11-04 2012-02-24 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents which is an agonist of Toll-Like Receptor 7
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
CA2640248A1 (en) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg. Influenza vaccines containing hemagglutinin and matrix proteins
WO2007100634A2 (en) 2006-02-22 2007-09-07 3M Innovative Properties Company Immune response modifier conjugates
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
WO2007109813A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2007765B1 (en) * 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
EP2010530A2 (en) * 2006-03-23 2009-01-07 Novartis AG Methods for the preparation of imidazole-containing compounds
US20100068223A1 (en) 2006-03-24 2010-03-18 Hanno Scheffczik Storage of Influenza Vaccines Without Refrigeration
EP2382988A1 (en) 2006-03-31 2011-11-02 Novartis AG Combined mucosal and parenteral immunization against HIV
JP2009534309A (ja) 2006-03-31 2009-09-24 マサチューセッツ インスティテュート オブ テクノロジー 治療剤の標的化送達のためのシステム
TW200808739A (en) * 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
CN101426514A (zh) * 2006-04-25 2009-05-06 英特塞尔股份公司 Hcv疫苗
EP2019691B1 (en) 2006-05-15 2020-08-12 Massachusetts Institute of Technology Polymers for functional particles
CA2653941C (en) 2006-05-31 2013-01-08 The Regents Of The University Of California Substituted amino purine derivatives and uses thereof
EP2035035A2 (en) 2006-06-09 2009-03-18 Novartis AG Immunogenic compositions for streptococcus agalactiae
US9381477B2 (en) * 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
EP2502628B1 (en) 2006-06-23 2016-12-14 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
WO2008019142A2 (en) * 2006-08-04 2008-02-14 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
US8178539B2 (en) 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
EP2497495B3 (en) 2006-09-11 2021-02-17 Seqirus UK Limited Making influenza virus vaccines without using eggs
EP2121011B1 (en) 2006-12-06 2014-05-21 Novartis AG Vaccines including antigen from four strains of influenza virus
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EA019151B1 (ru) 2007-02-07 2014-01-30 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Конъюгаты синтетических агонистов tlr и их применение
EP2134830A2 (en) 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oscillating cell culture bioreactor
US20090074828A1 (en) * 2007-04-04 2009-03-19 Massachusetts Institute Of Technology Poly(amino acid) targeting moieties
CN101784655A (zh) * 2007-04-27 2010-07-21 菲尼克斯股份有限公司 可溶性重组二十面体病毒样颗粒的改良生成和体内装配
DK2185191T3 (da) 2007-06-27 2012-12-03 Novartis Ag Influenzavacciner med lavt indhold af tilsætningsstoffer
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CA2917512C (en) 2007-10-12 2025-08-05 President And Fellows Of Harvard College VACCINE NANOTECHNOLOGY
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
JP2011511073A (ja) * 2008-02-07 2011-04-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｔｌｒ７活性化物質による膀胱の疾患の治療
AU2009227674C1 (en) 2008-03-18 2015-01-29 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en) * 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US9855291B2 (en) 2008-11-03 2018-01-02 Adc Therapeutics Sa Anti-kidney associated antigen 1 (KAAG1) antibodies
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
EP2396328A2 (en) 2009-02-11 2011-12-21 The Regents of The University of California Toll-like receptor modulators and treatment of diseases
AU2010220103A1 (en) 2009-03-06 2011-09-22 Novartis Ag Chlamydia antigens
DK2510947T3 (en) 2009-04-14 2016-03-21 Glaxosmithkline Biolog Sa Compositions for Immunization against Staphylococcus aureus.
CN102548577A (zh) 2009-04-27 2012-07-04 诺华有限公司 用于抵抗流感的佐剂疫苗
CN102639147B (zh) 2009-07-15 2015-11-25 诺华股份有限公司 Rsv f 蛋白组合物和其制作方法
CA2768343A1 (en) 2009-07-16 2011-01-20 Novartis Ag Detoxified escherichia coli immunogens
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
CA2798323A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
RS55819B1 (sr) 2010-08-17 2017-08-31 3M Innovative Properties Co Kompozicije sa lipidiranim modifikatorom imuno-odgovora, formulacije, i postupci
EP2640190A4 (en) 2010-11-05 2016-05-11 Selecta Biosciences Inc MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
PT2667892T (pt) 2011-01-26 2019-06-07 Glaxosmithkline Biologicals Sa Regime de imunização contra o vsr
SMT201900505T1 (it) 2011-03-31 2019-11-13 Adc Therapeutics Sa Anticorpi contro l'antigene 1 associato ai reni e loro frammenti leganti l'antigene
SG194755A1 (en) 2011-05-13 2013-12-30 Novartis Ag Pre-fusion rsv f antigens
WO2012167088A1 (en) 2011-06-03 2012-12-06 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
AU2012261959B2 (en) 2011-06-03 2015-12-03 Solventum Intellectual Properties Company Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
MX2014001142A (es) 2011-07-29 2014-02-27 Selecta Biosciences Inc Nanoportadores sinteticos que generan respuestas inmunitarias humorales y de linfocitos t citotoxicos (ctl).
CA2854934A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
PL2794627T3 (pl) 2011-12-22 2019-04-30 Alios Biopharma Inc Podstawione nukleozydy, nukleotydy i ich analogi
CA2857400A1 (en) 2012-01-09 2013-07-18 Alethia Biotherapeutics Inc. Anti-kaag1 antibodies or antigen binding fragment thereof for treatment of triple negative breast cancer
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
SG11201406592QA (en) 2012-05-04 2014-11-27 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
EP2762158A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation E75-vaccine composition for transdermal administration
KR102045029B1 (ko) 2013-02-05 2019-11-14 닛토덴코 가부시키가이샤 점막 투여용 ｗｔ1 펩티드 암 백신 조성물
EP2762156A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Tape preparation of WT1 peptide cancer vaccine for transdermal administration
IN2014CH00396A (cg-RX-API-DMAC7.html) 2013-02-05 2015-04-03 Nitto Denko Corp
EP2762161A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation E75-vaccine composition for mucosal administration
RU2014102939A (ru) 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Вакцинная композиция для чрескожного введения
CN103961699B (zh) 2013-02-05 2018-11-06 日东电工株式会社 经皮给予用wt1肽癌症疫苗组合物
KR20140100419A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 조성물
CN103961698A (zh) 2013-02-05 2014-08-06 日东电工株式会社 经皮或粘膜给予用疫苗组合物
RU2014102941A (ru) 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Вакцинная композиция для введения через слизистую оболочку
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン
WO2015144655A1 (en) 2014-03-26 2015-10-01 Glaxosmithkline Biologicals S.A. Immunising against staphylococcus aureus
KR102161364B1 (ko) 2015-09-14 2020-09-29 화이자 인코포레이티드 LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
US11306083B2 (en) 2017-12-20 2022-04-19 3M Innovative Properties Company Amide substituted imidazo[4,5-C]quinoline compounds with a branched chain linking group for use as an immune response modifier
WO2021226088A1 (en) * 2020-05-05 2021-11-11 Virovax Llc Vaccine adjuvants

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1271477A (en) * 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4716168A (en) * 1985-01-08 1987-12-29 Norwich Eaton Pharmaceuticals, Inc. Imidazo(4,5-f)quinolines useful as immunomodulating agents
US4689224A (en) * 1985-10-07 1987-08-25 Neogen Corporation Method for administering vaccines containing equine leukokines and compositions therefor
US4619827A (en) * 1985-10-07 1986-10-28 Neogen Corporation Method for administering equine vaccines and compositions therefor
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
EP0273512B1 (en) * 1986-12-19 1991-02-27 Duphar International Research B.V Stabilised adjuvant suspension comprising dimethyl dioctadecyl ammonium bromide
EP0283085B1 (en) * 1987-03-17 1992-11-11 Akzo N.V. Adjuvant mixture
US5149529A (en) * 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
IL92537A (en) * 1988-12-15 1994-04-12 Riker Laboratories Inc Topical preparations and dermal systems containing 1-isobutyl-H1-imidazo [C-4,5] quinoline-4-amine
DK0385630T3 (da) * 1989-02-27 1997-05-12 Riker Laboratories Inc 1H-imidazo(4,5-c)quinolin-4-aminer som antivirale midler
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5037986A (en) * 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
NZ232740A (en) * 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US5015476A (en) * 1989-08-11 1991-05-14 Paravax, Inc. Immunization implant and method
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006015585A1 (de) * 2006-04-04 2007-10-18 Mahle International Gmbh Kolben für einen Verbrennungsmotor

Also Published As

Publication number Publication date
JPH07505883A (ja) 1995-06-29
JP3732506B2 (ja) 2006-01-05
HUT69993A (en) 1995-09-28
AU674313B2 (en) 1996-12-19
EP0636031A1 (en) 1995-02-01
HK1007962A1 (en) 1999-04-30
HU217209B (hu) 1999-12-28
NO943920L (no) 1994-10-14
JP2004043496A (ja) 2004-02-12
EP0636031B1 (en) 1996-09-04
KR100263804B1 (ko) 2000-08-16
HU9402978D0 (en) 1995-02-28
WO1993020847A1 (en) 1993-10-28
IL105325A0 (en) 1993-08-18
ZA932627B (en) 1994-10-14
DE69304521D1 (de) 1996-10-10
CA2118239C (en) 2009-04-07
NO943920D0 (no) 1994-10-14
US6083505A (en) 2000-07-04
DE69304521T2 (de) 1997-02-20
CA2118239A1 (en) 1993-10-28
NZ280098A (en) 1998-06-26
HU211298A9 (en) 1995-11-28
IL105325A (en) 1996-11-14
AU4048093A (en) 1993-11-18
ES2092306T3 (es) 1996-11-16
NO313864B1 (no) 2002-12-16
MX9302199A (es) 1994-08-31
NZ252020A (en) 1995-12-21
DK0636031T3 (cg-RX-API-DMAC7.html) 1997-02-24

Similar Documents

Publication Publication Date Title
DE69304521D1 (de) Impfstoff Adjuvans
KR900011476A (ko) 백신 제제
IT1205820B (it) Adiuvante immunologico per vaccini polisaccaridici
PL304419A1 (en) Urease based vaccine against heliobacter infections
IT8921888A0 (it) Dispositivo per la coltivazione di piante.
PT73740A (en) Novel benzoxazolinones substituted in the 6-position by an amino-alcohol chain or amino-ketone chain their preparation and their use in pharmaceutical preparations
FI893479A7 (fi) Turvallinen ymppäyslaite
DK633087A (da) Konjugeret vaccine
IT8723085A0 (it) Epitopo immunodominante protettivo contenuto nella subunita' s1 della tossina della pertosse.
ATE134386T1 (de) Vakzin-zusammensetzung
NZ219631A (en) Vaccine composition with interferon as adjuvant
IT8748220A0 (it) Dispositivo di sicurezza per il gruppo di lavoro di mietitrici agricole
IT1177974B (it) Composizione comprendente endotossina detossificata raffinata
IT1208369B (it) Dispositivo per la regolazione di un sedile per trattamenti odontoiatrici
GR3021983T3 (en) Cross-reactive influenza a immunization
BR8705651A (pt) Conjunto projetado para ser conduzido no braco sobre as vestes
NO891649D0 (no) Anordning med tannstangsheis.
IT1181512B (it) Dispositivo di regolazione dell'altezza nelle poltrone
IT217731Z2 (it) Dispositivo autoirrorante per colture da vaso o simili.
IL87933A0 (en) Compositions for stimulating the immune system
IT8205210A0 (it) Dispositivo di ritorno per piani girevoli di sedie e poltrone pesanti o fisse al pavimento.
IT8464234V0 (it) Dispositivo di regolazione dell'altezza nelle poltrone.
IT8903399A0 (it) Dispositivo per l'irrigazione controllata di piante, in particolare per piante da balcone simili
IE853251L (en) Vaccine with oil-enhanced antigenicity
IT8160302V0 (it) Dispositivo per migliorare la posizione degli arti superiori nelle sedie a sdraio.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification